Literature DB >> 15661028

FOXP3 acts as a rheostat of the immune response.

Hans D Ochs1, Steven F Ziegler, Troy R Torgerson.   

Abstract

The study of a rare human X-linked disease resulting in a characteristic clinical phenotype of multiple autoimmune disorders and the in-depth exploration of a spontaneous mouse model, scurfy (sf), have contributed to a better understanding of the regulation of immunologic responses, particularly to self. Forkhead box P3 (FOXP3), the gene responsible for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) and sf is located on the X chromosome and is of crucial importance for the generation of CD4+ CD25+ regulatory T cells. Loss of FOXP3 function and the resultant lack of regulatory T cells result in lethal auto-aggressive lymphoproliferation, whereas overexpression of this modulator results in severe immunodeficiency. The in-depth analysis of FOXP3 regulation and elucidation of the precise mechanisms by which FOXP3 exerts its regulatory effect will provide important insights into the understanding of autoimmunity and should predictably result in new therapeutic possibilities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661028     DOI: 10.1111/j.0105-2896.2005.00231.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  61 in total

Review 1.  Treg vaccination with a strong-agonistic insulin mimetope.

Authors:  Benno Weigmann; Carolin Daniel
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

2.  Perspectives on Regulatory T Cell Therapies.

Authors:  Michael Probst-Kepper; Andrea Kröger; Henk S P Garritsen; Jan Buer
Journal:  Transfus Med Hemother       Date:  2009-09-10       Impact factor: 3.747

Review 3.  Regulatory T cells: roles of T cell receptor for their development and function.

Authors:  Naganari Ohkura; Shimon Sakaguchi
Journal:  Semin Immunopathol       Date:  2010-02-24       Impact factor: 9.623

Review 4.  Immunity to microbes: lessons from primary immunodeficiencies.

Authors:  Magda Carneiro-Sampaio; Antonio Coutinho
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

5.  Notch ligand delta-like 4 blockade alleviates experimental autoimmune encephalomyelitis by promoting regulatory T cell development.

Authors:  Ribal Bassil; Bing Zhu; Youmna Lahoud; Leonardo V Riella; Hideo Yagita; Wassim Elyaman; Samia J Khoury
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

6.  FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby limiting effector cytokine expression.

Authors:  Troy R Torgerson; Anna Genin; Chunxia Chen; Mingce Zhang; Bin Zhou; Stephanie Añover-Sombke; M Barton Frank; Igor Dozmorov; Elizabeth Ocheltree; Petri Kulmala; Michael Centola; Hans D Ochs; Andrew D Wells; Randy Q Cron
Journal:  J Immunol       Date:  2009-06-29       Impact factor: 5.422

Review 7.  Laboratory diagnosis of primary immunodeficiencies.

Authors:  Bradley A Locke; Trivikram Dasu; James W Verbsky
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

8.  Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.

Authors:  Yuya Hashimura; Kandai Nozu; Hirokazu Kanegane; Toshio Miyawaki; Akira Hayakawa; Norishige Yoshikawa; Koichi Nakanishi; Minoru Takemoto; Kazumoto Iijima; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2009-02-03       Impact factor: 3.714

9.  Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway.

Authors:  Kevin M Elias; Arian Laurence; Todd S Davidson; Geoffrey Stephens; Yuka Kanno; Ethan M Shevach; John J O'Shea
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

10.  Domain requirements and sequence specificity of DNA binding for the forkhead transcription factor FOXP3.

Authors:  Kian Peng Koh; Mark S Sundrud; Anjana Rao
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.